KRONOX173.00

Kronox Lab Sciences Limited

· Chemicals
AnnualQuarterly₹ CrorePeersJAYAGROGNDMCCSRHHYPOLTDCHEMFABPRIMOPLASTIBLENGEMAROMASUDARCOLORMcap ₹642 Cr
View
In ₹ Crore except Per Share
12 Months Ending
Q4 FY24
31/03/2024
Q1 FY25
30/06/2024
Q2 FY25
30/09/2024
Q3 FY25
31/12/2024
Q4 FY25
31/03/2025
Q1 FY26
30/06/2025
Q2 FY26
30/09/2025
Q3 FY26
31/12/2025
Q4 FY26
31/03/2026
Q1 FY27
30/06/2026
Revenue from Operations22.225.224.924.026.124.325.525.326.128.4
Other Income0.80.40.40.80.90.91.01.12.11.3
Total Income23.025.625.224.827.025.226.626.428.329.7
Expenses
+ Cost of Materials Consumed12.112.310.912.513.012.910.212.711.315.1
+ Changes in Inventories-1.61.10.4-0.71.4-1.11.1-0.80.4-1.1
+ Employee Benefit Expense1.21.21.21.21.21.81.82.11.61.9
+ Finance Costs0.00.00.00.00.00.00.00.00.00.0
+ Depreciation & Amortisation0.30.30.30.40.40.40.50.50.70.5
+ Other Expenses2.62.43.62.62.82.83.73.23.33.5
Total Expenses14.617.316.416.018.716.717.417.817.319.9
EBITDA7.98.28.88.47.78.08.68.09.59.0
EBIT7.67.98.58.07.47.68.27.58.98.5
Profit
PBT before Exceptional Items8.48.38.88.88.38.49.28.611.09.8
Pretax Income8.48.38.88.88.38.49.28.611.09.8
+ Current Tax2.32.22.32.32.22.22.52.13.02.5
+ Deferred Tax0.2-0.00.10.0-0.2-0.00.0-0.10.0-0.0
Tax Expense2.52.22.32.32.02.22.52.03.02.5
Net Income5.96.26.56.56.36.36.76.68.07.3
+ Net Income — Continuing Ops5.96.26.56.56.36.36.76.68.07.3
+ Other Comprehensive Income0.10.00.00.00.10.00.10.10.1-0.0
Total Comprehensive Income6.06.26.56.66.46.36.76.68.17.3
Per Share
Basic EPS1.601.671.761.771.721.701.821.792.182.00
Diluted EPS1.601.671.761.771.721.701.821.792.182.00
Other Comprehensive Income — detail
+ Other Comprehensive Income0.10.00.10.10.1-0.0
+ Tax on Items NOT to be Reclassified-0.1-0.0-0.1-0.1-0.10.0
+ Tax on Items NOT to be Reclassified — alt tag-0.1-0.0-0.0-0.0
+ Tax on Items to be Reclassified0.00.00.00.00.0-0.0
Per Share — as-filed variants
Basic EPS — Continuing Operations1.601.671.761.771.721.701.821.792.182.00
Diluted EPS — Continuing Operations1.601.671.761.771.721.701.821.792.182.00
Regulatory Disclosures — filed alongside, not part of the P&L
Related-party Transactions — During the Period0.92.0
Derived — Gross Profit (Revenue − Materials − Purchases − Δ Inventories)
Gross Profit11.711.813.612.111.812.514.213.414.414.4
Gross Margin %52.7546.9254.5650.5344.9851.6055.4953.0555.2050.75
Adjusted (ex-Exceptional Items) — derived
Pretax Income (Adjusted, as filed)8.48.38.88.88.38.49.28.611.09.8
Net Income Adj (tax-effected)5.96.26.56.56.36.36.76.68.07.3
EPS Adj1.601.671.761.771.721.701.821.792.182.00
Other Filed Concepts — mapped but not yet placed in the schedule
Face Value10.0010.0010.0010.0010.0010.0010.0010.0010.0010.00
Paid Up Equity Capital3,71,040.03,71,040.037.137.137.137.137.137.137.137.1
As filed, sign as filed — read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown, so depth follows the filer: pre-Ind-AS, insurance and NBFC blocks stay hidden unless they were actually reported. Alternate tags for the same idea (e.g. two spellings of a deferred-tax element) are kept as separate lines rather than merged, because merging them would be a guess. Ratios, per-share figures and counts render as raw numbers, not ₹ Crore. No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: Q1 FY27 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreementXBRL cross-verified ✓ 95%.